Deployment o the Multidisciplinary Prospective Cohort Imminent

Launched by UNIVERSITY HOSPITAL, LILLE · Apr 2, 2020

Keywords

ClinConnect Summary

The IMMINeNT clinical trial is studying patients with chronic inflammatory diseases such as severe asthma, lupus, and multiple sclerosis. These conditions can greatly affect a person’s quality of life and often require special treatments. The goal of the trial is to create a comprehensive database and biobank that will help researchers find better ways to understand and treat these diseases. By collecting information from patients, the study aims to identify new biomarkers—substances that can indicate how the disease is progressing or how well treatments are working.

To participate in this trial, you need to be receiving care for one of these inflammatory diseases at Lille University Hospital. You should also be able to understand the study requirements and provide written consent. Unfortunately, some individuals, such as pregnant women or those unable to give consent, cannot participate. If you join, you can expect to provide some personal health information and possibly contribute to future advances in treatment for these challenging diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)
• • Social insured
• • Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.
• Exclusion Criteria:
• • Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system.
• • Pregnant or breastfeeding woman
• • Persons deprived of liberty
• • Protected minors or adults
• • Persons who have refused or are incapable of giving informed consent
• • Persons in Emergency Situations